Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.58 |
| ▸ | LMNA | P02545 | 7/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.55 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372181 | 1.00 | KDM4E (0.58) | KDM4ELMNARAB9ANPC1PKM | |
| SCHEMBL28443608 | 0.82 | RAB9A (0.80) | KDM4ELMNARAB9ANPC1PKM | |
| SCHEMBL5093237 | 0.81 | KDM4E (0.58) | KDM4ELMNARAB9ANPC1PKM | |
| SCHEMBL5093246 | 0.81 | KDM4E (0.58) | KDM4ELMNARAB9ANPC1PKM | |
| SCHEMBL1163276 | 0.81 | NPC1 (0.56) | KDM4ELMNARAB9ANPC1PKM | |
| SCHEMBL18050167 | 0.80 | KDM4E (0.49) | KDM4ELMNARAB9ANPC1PKM | |
| SCHEMBL18050160 | 0.80 | KDM4E (0.49) | KDM4ELMNARAB9ANPC1PKM | |
| Hydrochloric Acid SCHEMBL9872403 | 0.80 | KDM4E (0.56) | KDM4ELMNARAB9ANPC1PKM | |
| Hydrochloric Acid SCHEMBL7283431 | 0.80 | KDM4E (0.56) | KDM4ELMNARAB9ANPC1PKM | |
| SCHEMBL21038093 | 0.79 | KDM4E (0.54) | KDM4ELMNARAB9ANPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342026-B2 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (FR) | 2008-03-11 | — | — | US | disclosed |
| EP-1351940-B1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | INST RECH DEVELOPPEMENT IRD (FR) | 2007-07-25 | — | — | EP | disclosed |
| US-7067530-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| US-20050165052-A1 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1351940-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | Institut de Recherche pour le Développement ( IRD) (FR) | 2003-10-15 | — | — | EP | disclosed |
| US-20030109560-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2003-06-12 | — | — | US | disclosed |
| WO-2002057238-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD) (FR) | 2002-07-25 | — | — | WO | disclosed |
| US-5334597-A | Anti-asthmatic, antiallergic, antiinflammatory, cytoprotective treats angina, cerebral spasm, nephritis, hepatitis, uveitis, endotoxemia and allograft rejection | MERCK FROSST CANADA, INC. (CA) | 1994-08-02 | — | — | US | disclosed |
| EP-0538000-A1 | Indole and indazole carbamates as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-04-21 | — | — | EP | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165052-A1 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections | C1S, C5, NSFL1C | KDM4E 3607/4885LMNA 1106/4885RAB9A 1036/4885 |
| US-20030109560-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | KDM4E 3687/4885LMNA 1817/4885RAB9A 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.